Pepscan achieves milestones from Janssen

Saturday, February 11, 2012 07:53 AM

Pepscan Therapeutics, a Netherlands-based biotechnology firm focusing on protein mimicry technology, has achieved two milestones in the research collaboration with Janssen R&D Ireland, formerly Tibotec Pharmaceuticals, and received undisclosed payments. 

Pepscan has discovered novel peptides with potential therapeutic utility using its proprietary peptide array platform for high throughput synthesis and screening of “conformationally stabilized” CLIPS (Chemical LInkage of Peptides onto Scaffolds) peptides.

“The achievement of these milestones demonstrates the effectiveness of our high throughput peptide array technology for the discovery of novel peptides with excellent activity and proteolytic stability,” said Wim Mol, CEO of Pepscan. “We consider this achievement a further expression of our expertise in the field of peptide lead discovery and optimization.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs